H. Lundbeck A/S/DKr HLUN B
07:00
09:00
11:00
12:55
14:55
1D1W1MYTD1Y5YMAX
About H. Lundbeck A/S
H. Lundbeck A/S is a Danish pharmaceutical company specializing in the research, development, and marketing of products for the treatment of brain diseases. The company focuses on areas such as depression, schizophrenia, Alzheimer's disease, and Parkinson's disease. Founded in 1915, Lundbeck is headquartered in Valby, Denmark, and has a significant global presence with facilities across Europe, North America, and Asia. Lundbeck's strategic positioning is underscored by its dedicated emphasis on central nervous system disorders, supported by a robust pipeline of research and development projects. The company places a strong emphasis on scientific and clinical excellence, aiming to deliver innovative therapies to improve patient outcomes.
Ticker
DKr HLUN B
Sector
Primary listing
CSE
Employees
5,000
Headquarters
Valby, Denmark
Website
H. Lundbeck A/S Metrics
BasicAdvanced
kr 40bn
11.06
kr 3.76
0.26
kr 1.15
2.77%
Price and volume
Market cap
kr 40bn
Beta
0.26
52-week high
kr 47.78
52-week low
kr 35.30
Average daily volume
456k
Dividend rate
kr 1.15
Financial strength
Current ratio
1.407
Quick ratio
0.895
Long term debt to equity
42.355
Total debt to equity
42.644
Dividend payout ratio (TTM)
30.59%
Interest coverage (TTM)
19.81%
Profitability
EBITDA (TTM)
8,142
Gross margin (TTM)
82.44%
Net profit margin (TTM)
14.62%
Operating margin (TTM)
25.00%
Effective tax rate (TTM)
27.94%
Revenue per employee (TTM)
kr 5,100,000
Management effectiveness
Return on assets (TTM)
7.49%
Return on equity (TTM)
14.86%
Valuation
Price to earnings (TTM)
11.055
Price to revenue (TTM)
1.616
Price to book
1.56
Price to tangible book (TTM)
-3.82
Price to free cash flow (TTM)
8.546
Free cash flow yield (TTM)
11.70%
Free cash flow per share (TTM)
4.863
Dividend yield (TTM)
2.77%
Forward dividend yield
2.77%
Growth
Revenue change (TTM)
11.19%
Earnings per share change (TTM)
14.43%
3-year revenue growth (CAGR)
10.49%
10-year revenue growth (CAGR)
5.60%
3-year earnings per share growth (CAGR)
16.11%
10-year earnings per share growth (CAGR)
-3.77%
3-year dividend per share growth (CAGR)
25.63%
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Market data provided by CBOE Europe and Deutsche Börse.